Prospective animal studies or organoid models—feasible with existing xenograft platforms—would provide critical validation of the therapeutic potential of miR‐32‐5p inhibition and its impact on c‐MYC‐driven tumor biology. This evidence concerns the gene MYC and neoplasm.